CRISPR and reproductive screening

Parallel case: A 16-year-old with severe sickle cell disease is offered a CRISPR-based therapy. Doctors would remove some of the patient's own bone-marrow stem cells, use a guide RNA to steer Cas9 to a single gene (BCL11A) that switches off fetal hemoglobin, cut that gene, and let the cells' repair machinery disable it. The edited cells are grown and returned to the patient so their body makes protective fetal hemoglobin again. The patient and their guardians consent after counseling.\n\nClaim: In this case CRISPR-based somatic therapy is an appropriate treatment to offer, because the edit is limited to the patient's own body cells, is not passed to future generations, and is chosen with informed consent to treat serious ongoing harm.\n\nEvidence 1: The edit is somatic, not germline. It changes blood-forming cells in one person and is not inherited by that person's future children, so any mistake affects only the consenting patient and does not spread to descendants.\n\nEvidence 2: Off-target risk is real but is being managed and consented to. The guide RNA is about 20 letters long against a genome of roughly 3 billion letters, so Cas9 can cut a wrong site that partially matches, and a bad off-target cut could disrupt a tumor suppressor or another important gene. However, the edited cells can be screened before they are returned, and the patient is weighing that known risk against the daily harm of untreated sickle cell disease.\n\nReasoning: Because the change stays in one consenting person and is not heritable, the ethical stakes are lower than a change that every future generation would carry. The off-target danger does not disappear, but it can be reduced by checking the cells and is being accepted knowingly to relieve a serious, present illness. When a competent patient consents, the harm is severe, and the risk is bounded to that individual, offering the somatic edit is justified.